Tysabri Update from FDA
The FDA continues to receive reports of progressive multifocal leukoencephalopathy (PML) in patients receiving Tysabri.
The FDA continues to receive reports of progressive multifocal leukoencephalopathy (PML) in patients receiving Tysabri.
